Presentations demonstrate the potential of AdoShell® for allogenic cell therapy in diabetes without immunosuppression, by delivering pancreatic human islets or iPSCs1
New preclinical data support AdoShell® Islets progression toward First-In-Human clinical trial submission in 2025
Data to be presented at the American Diabetes Association’s (ADA) 85th Scientific Sessions, the International Pancreas and Islet Transplant Association (IPITA) World Congress, the European Islets Study Group (EISG), and the International Society for Cell & Gene Therapy (ISCT) Annual Meeting
LYON, France, April 28, 2025--(BUSINESS WIRE)--Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity (the "Company"), today announced the latest preclinical data from its innovative AdoShell® technology platform have been selected for presentations at four upcoming scientific conferences.
AdoShell® Islets is an innovative immunoprotective hydrogel designed to encapsulate pancreatic islets, with the goal of curing diabetes through cell therapy without requiring immunosuppression. This semi-permeable hydrogel allows the diffusion of insulin and glucose, while preventing the infiltration of antibodies and immune cells that would lead to graft rejection. Currently, to prevent this normal body reaction, every allogeneic transplant patient must take immunosuppressive drugs on a chronic basis, with significant side effects. AdoShell® is easily implantable and fully retrievable via laparoscopy.
The new data to be presented by Adocia notably disclose the success of the scale-up to deliver the therapeutic dose for the first-in-human study, which is planned to be submitted with the regulatory authorities in 2025.
In addition, new in vitro and in vivo data to be presented confirm the compatibility of AdoShell® with stem cell-derived islets, notably their ability to mature into insulin producing cells within AdoShell®. The integration of these stem cell-derived islets into our technology represents a key step toward broader access to type 1 diabetes treatment through cell therapy, without the need for immunosuppression.
Adocia envisions that AdoShell® could be applied beyond pancreatic cells to other cell types. Data with primary and differentiated stem cells for the release of various therapeutic molecules other than insulin will also be presented, illustrating the possibility to make AdoShell® a technology platform.
International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting, New Orleans, USA, May 7-10, 2025
AdoShell®, a non-fibrotic encapsulation system for cell delivery
Session: Tissue Engineering; Embryonic, Organ and Other Tissue Specific Stem Cells
Presentation: Friday, May 9, 2025, 8:00 AM to 9:00 AM (CDT)
Ouardane Jouannot, Julie Brun, Romain Besnard, Clément Cocita, Alexandre Martin, Camille Gautier, Jonna Saarimäki-Vire, Timo Otonkoski, Diego Balboa, Nicolas Laurent, Anne-Lise Gaffuri, Rosy Eloy, Karim Bouzakri, François Pattou, Olivier Soula
European Islet Study Group (EISG) 2025, Malmö, Sweden, June 11-13, 2025
AdoShell®: A Permselective and Non-Fibrotic Scaffold for Human Islet Transplantation
Poster session
Clément Cocita, Ouardane Jouannot, Julie Brun, Camille Gautier, Nicolas Laurent, Karim Bouzakri, Jonna Saarimäki-Vire, Timo Otonkoski, Diego Balboa, Anne-Lise Gaffuri, Rosy Eloy, Olivier Soula
International Pancreas and Islet Transplant Association (IPITA) 2025 World Congress, Pisa, Italy, June 15-18, 2025
AdoShell®, a non-fibrotic encapsulation system for human islet transplantation without immunosuppression
Session: OP_03 Bioengineering the Future of Diabetes Therapy: 3D Printing, Organoids, and Immune-Protective Implants
Presentation: Monday, June 16, 2025 - 12:00 PM (CEST)
Ouardane Jouannot, Alexandre Martin, Julie Brun, Madeleine Frêlon, Camille Gautier, Guillaume Lefebvre, Romain Besnard, Clément Cocita, Claire Megret, Nicolas Laurent, Anne-Lise Gaffuri, Martin Gaudier, Rosy Eloy, François Pattou, Olivier Soula.
American Diabetes Association’s (ADA) 85th Scientific Sessions, Chicago, USA, June 20-23, 2025
AdoShell®, a non-fibrotic encapsulation system, enables stem cell-derived islets in vivo maturation for T1DM treatment
Session: Innovation and Progress in Stem Cell–Derived Islet-Cell Replacement Therapy
Presentation: 139‑OR, Friday, June 20, 2025, 6:00 PM (CDT)
Ouardane Jouannot, Julie Brun, Clément Cocita, Alexandre Martin, Camille Gautier, Jonna Saarimäki-Vire, Timo Otonkoski, Diego Balboa, Nicolas Laurent, Anne-Lise Gaffuri, Rosy Eloy, Karim Bouzakri, Olivier Soula
Note: all information contained in the submitted abstracts should be considered preliminary and subject to change until the study data and observations are fully presented at the specified conferences. The abstracts are subject to embargo.
About Adocia
Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity.
The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone® technology for the development of new generation insulins and products combining different hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoGel®, a long-acting drug delivery platform.
Adocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia is listed on the regulated market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241).
Disclaimer
This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers as being reasonable. However, there can be no guarantee that the estimates contained in such forward-looking statements will be achieved, as such estimates are subject to numerous risks including those set forth in the "Risk Factors" section of the universal registration document that was filed with the French Autorité des marchés financiers on April 29, 2024, as updated in the Company’s 2024 Half-year financial statements, published on September 19, 2024, both available at www.adocia.com.Those risks include uncertainties inherent in Adocia's short- or medium-term working capital requirements, in research and development, future clinical data, analyses and the evolution of economic conditions, the financial markets and the markets in which Adocia operates, which could impact the Company's short-term financing requirements and its ability to raise additional funds. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not considered as material by Adocia at this time. The occurrence of all or part of such risks could cause the actual results, financial conditions, performances, or achievements of Adocia be materially different from those mentioned in the forward-looking statements. This press release and the information it contains do not constitute an offer to sell or subscribe for, or the solicitation of an order to buy or subscribe for, Adocia shares in any country.
